Bryan Garnier - CALLIDITAS THERAPEUTICS AB (CALT) Calliditas: Asahi Kasei to acquire CALTX

Report

Bryan Garnier

Oscar Haffen Lamm

Calliditas: Asahi Kasei to acquire CALTX

Asahi Kasei today announced a public cash offer to acquire all shares in Calliditas for SEK 208/share (+83% premium), representing a total value of SEK 11.164bn. The Offer will also include a concurrent offer to acquire all ADS for SEK 416/ADS (+74% premium). We believe that the offer fully recogni

28/05/2024 1 EN

Underlying

CALLIDITAS THERAPEUTICS AB

See profile

US13124Q1067 Non National NASDAQ Stock Exchange Sweden

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Oscar Haffen Lamm

Other Reports on these Companies

Bryan Garnier

Calliditas: despite weaker Q1 sales, patient enrolment is showing steady progress and is key at this stage

Tarpeyo Q1 2024 sales reached SEK278.3m (USD28m), representing a 20% decrease vs the previous quarter, primarily due to the cyberattack that Change Healthcare (part of the United Group) suffered in February 2024, which lead to disruptions in claim processing (approx. USD4.7m). As such, some of Q1 s

May 23, 2024 May 23, 2024 1 EN

Bryan Garnier

CALLIDITAS: Cautious guidance leaves room for surprise as Tarpeyo enters 2024 with good momentum

Yesterday, Calliditas reported its Q4 Tarpeyo sales reaching SEK 347.3m (USD 32.6m), with total net sales at SEK 1.206bn for FY 2023, in line with the USD 100-120m guidance, and a cash position at SEK 973.7m. All in all, the Q4 performance was solid, while the main surprise came with the conservati

February 22, 2024 February 22, 2024 1 EN

Alfen: Lowered FY24 outlook

This morning, Alfen has adjusted its FY24 revenue and EBITDA guidance, now eyeing EUR485-520m revenue (-19% vs previous range at EUR590-660m) with mid-single-digit adjusted EBITDA and negative FCF (vs >11.3% and positive FCF), below the consensus at EUR599m revenue with 11% EBITDA. Medium-term o

3h / 10m 3h / 10m 1 EN

Bruno Bulic ... (+2)

Bruno Bulic
Oscar Haffen Lamm

Camurus: post hoc analysis shows Brixadi's effectiveness in fentanyl users

Camurus published in JAMA Network Open (here) a new post hoc analysis comparing weekly and monthly SC Buvidal/Brixadi injections to daily sublingual buprenorphine/naloxone, where the data presented suggests the effectiveness in individuals with opioid dependence who use fentanyl is consistent with

3h / 34m 3h / 34m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Ebusco: FY24 profit warning

Following yesterday's profit warning for FY24, with Ebusco stating its FY24 guidance (revenue >EUR325m with positive EBITDA) is no longer achievable, we revise our 2024-2026 revenue and margin sequence. Indeed, whereas the strategic shift to contract manufacturing is proving to be the right choi

3h / 40m 3h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Calliditas: Asahi Kasei to acquire CALTX

Calliditas: despite weaker Q1 sales, patient enrolment is showing steady progress and is key at this stage

CALLIDITAS: Cautious guidance leaves room for surprise as Tarpeyo enters 2024 with good momentum

Alfen: Lowered FY24 outlook

Camurus: post hoc analysis shows Brixadi's effectiveness in fentanyl users

Ebusco: FY24 profit warning

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe